Defining the Critical Hurdles in Cancer Immunotherapy

ABSTRACT: Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators, others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet be overcome to improve outcomes of patients with cancer

Recent advancement in modern genomic tools for adaptation of Lablab purpureus L to biotic and abiotic stresses: present mechanisms and future adaptations

Not AvailableHyacinth bean is an important traditional plant with substantial medicinal value. Being imperative, it is still less explored crop on genomic and transcriptomic scale that has indexed it as an “orphan” crop for its genome revolution. Among different crop legumes such as pigeon pea, chickpea, cowpea, soybean and common bean, hyacinth bean also serves as a significant source of nutrition for both tropical and temperate regions and execute an imperative function in fixing biological nitrogen in agriculture. Nonetheless, the productivity of hyacinth bean is restrained due to environmental and biotic cues. Thus, understanding of the genomic functions and identification of probable genes/proteins for major agronomic traits through transcriptomic approaches has become imperative to improve stress tolerance in hyacinth bean. For understanding the plant stress tolerance mechanisms, the deployment of functional genomics approaches viz., proteomics and metabolomics have become imperious in breeding programs in developing countries. These approaches have been successfully used in other legume crops to create protein reference maps and their exploitation through comparative approaches can greatly enhance the research and understanding of hyacinth bean biological processes to changing environmental conditions. In this review, emerging epigenomics, proteomics, metabolomics and phenomics approaches and their achievements both in model/crop legumes are discussed. Additionally, the review also provides an overview of the applications of advanced proteomics, metabolomics and next-generation sequencing technologies in the discovery of candidate biomarkers for the development of agronomically refined hyacinth bean which may further ensure food and nutritional security under adverse climacteric conditions in developing countries.Not Availabl